Safety and efficacy assessments
Tumors, Tumor
TUMORS, ADVERSE EVENT, TUMOR
Adverse events (AEs) were assessed and graded according to the CTCAE (version 5.0) throughout the study and up to 90 days after the last dose, including incidence and severity of treatment-emergent AEs (TEAEs). Antitumor activity of QL1604 was evaluated by investigators on the basis of Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Tumor responses were performed by computed tomography or magnetic resonance imaging at screening and every 6 weeks during the first 6 months and every 12 weeks thereafter.